Study of Pegylated Interferon Alpha Treatment for Adults with Essential Thrombocythemia and Polycythemia Vera in China

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Peginterferon alpha-2b in adults with Essential Thrombocythemia ET and Polycythemia Vera PV, two blood disorders characterized by abnormal blood cell production. This single-arm, single-center study aims to enroll 40 participants diagnosed according to specific 2016 WHO criteria. The study focuses on monitoring hematologic remission and other disease-related outcomes over time. Participants will receive a weekly subcutaneous injection of Peginterferon alpha-2b at a dose of 180 mcg. The investigator may adjust the dose based on any adverse events experienced. The study includes follow-up visits to assess the drugs impact on molecular markers, blood cell counts, spleen size, and the occurrence of complications such as thrombosis or progression to other blood diseases. During the study, participants will undergo evaluations at various time points up to 48 weeks, including blood tests to measure remission rates, gene mutation burden, and safety assessments. Researchers will also monitor for bleeding events and disease progression. The total duration of participation and detailed monitoring are designed to understand both the benefits and risks of this treatment in this patient group.

Efficacy and Safety of Peginterferon in ET and PV.